Clinical Trials
33 trialsNCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT04582539 2025-10-22
LIMBER
Incyte Corporation
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05735704 2025-03-26
SANGUINE
JaxBio Ltd
Unknown
NCT02649790 2025-03-19
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
Phase 1/2 Completed
NCT01943851 2024-10-01
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
GlaxoSmithKline
Phase 2 Completed
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT03465540 2023-04-12
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
Phase 1 Terminated
NCT04543305 2022-11-15
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT02477878 2022-07-12
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
Phase 1 Active not recruiting
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT04014764 2022-04-05
(ANSWer)
Notable Labs
Completed
NCT02587598 2021-12-08
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT01663766 2021-08-19
Phase I Study of Milatuzumab for Graft Versus Host Disease
Gilead Sciences
Phase 1 Terminated
NCT01953692 2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00967343 2021-06-14
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Phase 2/3 Terminated
NCT01930162 2021-01-05
UCBT
Novartis
Phase 2 Completed
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02164071 2019-11-18
GAH
Celgene
Completed
NCT00761722 2019-11-08
RACE
Celgene
Phase 1 Completed
NCT02431260 2019-06-14
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02203825 2018-06-01
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Celyad Oncology SA
Phase 1 Completed
NCT02842229 2017-07-26
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
Celgene
Completed
NCT02240537 2016-04-19
BBMPI03
Benovus Bio, Inc.
Phase 1 Unknown
NCT01413568 2016-02-26
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
Phase 1/2 Completed
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated
NCT01344707 2015-04-01
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
4SC AG
Phase 1 Completed
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00807677 2013-07-02
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00689000 2010-10-22
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
Chroma Therapeutics
Phase 1/2 Completed